Assembly Biosciences to Highlight Epson Robots' Automation Solutions at ASSEMBLY Show 2025
- Epson Robots will showcase automation solutions and SCARA technology at The ASSEMBLY Show 2025 in Illinois.
- Attendees can participate in hands-on demonstrations and educational sessions on robotic automation and ROI.
- Epson aims to address labor shortages and enhance manufacturing efficiency through innovative automation solutions.
Epson Robots to Showcase Automation Solutions at ASSEMBLY Show 2025
Epson Robots, a leader in SCARA (Selective Compliance Assembly Robot Arm) technology, prepares to present its cutting-edge automation solutions at The ASSEMBLY Show 2025, set for October 21-23 in Rosemont, Illinois. With a notable history of over 40 years in the automation industry, Epson aims to address pressing challenges faced by manufacturers, including labor shortages and the demands of reshoring production. The company’s commitment to providing efficient, adaptable, and reliable automation solutions positions it as a crucial partner for manufacturers navigating an increasingly competitive landscape.
At booth #319, attendees will have the opportunity to engage in hands-on demonstrations of Epson's advanced SCARA and 6-Axis robots. These robots are engineered to enhance manufacturing speed, safety, and overall efficiency. Scott Marsic, group product manager at Epson Robots, underscores the company’s mission to simplify automation, making it both accessible and cost-effective for businesses of all sizes. This initiative not only reflects Epson's innovative spirit but also its dedication to helping manufacturers streamline their operations and improve productivity in a time of heightened demand for agile manufacturing practices.
In addition to showcasing its technology, Epson hosts two educational sessions designed to empower manufacturers with essential knowledge about robotic automation. The first session, titled "Beyond the Labor: Understanding Robot ROI from Production to Profits," is scheduled for October 21, where Marsic will discuss the intricacies of calculating the return on investment (ROI) associated with robotic automation. The second session, "Automation 101: The Starting Point for Robot Automation," serves as a comprehensive guide for manufacturers looking to integrate robotics into their assembly processes. Through these sessions, Epson aims to equip industry professionals with the tools and insights necessary to navigate the complexities of modern manufacturing effectively.
As the manufacturing sector continues to evolve, Epson Robots remains at the forefront, championing the integration of automation technology. The forthcoming ASSEMBLY Show 2025 serves as a vital platform for Epson to demonstrate its solutions and educate attendees, reinforcing its role as a leader in the automation industry.
In related news, the ongoing discussions surrounding labor shortages in manufacturing highlight the urgency for innovative solutions. Many companies are increasingly turning to automation to fill gaps left by workforce challenges, making events like The ASSEMBLY Show integral for sharing knowledge and best practices.
Overall, Epson's commitment to high-performance robotics and educational outreach showcases its dedication to driving long-term gains in productivity and profitability for manufacturers across various industries.
Related Cashu News

Bristol-Myers Squibb's Reclassification Enhances Growth Potential in Defensive Investment Strategy
Bristol-Myers Squibb Company (Ticker: BMY) undergoes a key reclassification across the Russell indexes, marking a transformative moment for the company. Moving to the Russell 1000 Defensive and Russel…

Vertex Pharmaceuticals' Casgevy Gains FDA Approval for Expanded Sickle Cell Disease Treatment Options
Vertex Pharmaceuticals (Ticker: VRTX) receives a significant boost in its ongoing battle against sickle cell disease with the recent FDA approval of an expanded label for its gene therapy product, Cas…

Gilead Sciences Gains FDA Approval for Trodelvy in First-Line Triple-Negative Breast Cancer Treatment
Gilead Sciences (Ticker: GILD) makes significant strides in oncology therapy with the recent approval of its drug Trodelvy for patients with unresectable or metastatic triple-negative breast cancer. T…

Merck Advances HIV Treatment and Faces Regulatory Scrutiny Amidst Market Success
Merck & Co. (Ticker: MRK) has recently made significant strides in the pharmaceutical landscape, particularly with its advancements in HIV treatment. The company's innovative drug, IDVYNSO, has receiv…